PANBELA THERAPEUTICS INC (PBLA) 1.53 +0.1 (+6.99%)
1.53 +0.1 (+6.99%)
US69833W1071 - Common Stock - After market: 1.91 +0.38 (+24.84%)
Fundamental Rating
We assign a fundamental rating of 0 out of 10 to PBLA. PBLA was compared to 639 industry peers in the Biotechnology industry. PBLA has a bad profitability rating. Also its financial health evaluation is rather negative. PBLA is valued expensive and it does not seem to be growing.
Note: PBLA has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
The Piotroski-F score of PBLA is 2.00. This is a very weak score and indicates problems in health and profitability for PBLA.
VS Industry
Valuation
Valuation Rating
PBLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PBLA. No positive earnings are expected for the next year.
VS Industry
Growth
Growth Rating
PBLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -221.43%.
Based on estimates for the next 5 years, PBLA will show a very negative growth in Earnings Per Share. The EPS will decrease by -144.42% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -221.43% | -78.21% | 23.02% | 10.02% | -144.42% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
PBLA has a Current Ratio of 0.22. This is a bad value and indicates that PBLA is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.21, PBLA is worse placed to pay its short term obligations than its industry peers. 99% of its industry peers have a better Current Ratio.
PBLA has a Quick Ratio of 0.22. This is a bad value and indicates that PBLA is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of PBLA to the average industry Current Ratio of 6.11, PBLA is less able to pay its short term obligations than its industry peers. 99% of its industry peers have a better Quick Ratio.
Based on the Altman-Z score of -48.16, we must say that PBLA is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of PBLA to the average industry Altman-Z score of -0.13, PBLA is less financially healthy than its industry peers. 99% of its industry peers have a better Altman-Z score.
The Piotroski-F score of PBLA is 2.00. This is a very weak score and indicates problems in health and profitability for PBLA.
VS Industry
Quick Ratio (0.22) VS Industry: 1% outperformed.
0.04
84.53
Current Ratio (0.22) VS Industry: 1% outperformed.
0.08
85.09
Altman-Z (-48.16) VS Industry: 1% outperformed.
-94.22
622.88
Dividend
Dividend Rating
PBLA does not give a dividend.
PANBELA THERAPEUTICS INC1.53
NASDAQ:PBLA (1/30/2023, 7:14:06 PM)+0.1 (+6.99%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-10 2022-11-10/amc | Earnings (Next) | 03-22 2023-03-22 |
| Inst Owners | N/A | Inst Owner Change | N/A |
| Ins Owners | 85.76% | Ins Owner Change | 4.85% |
| Market Cap | 1.21M | Analysts | 80 |
| Price Target | 387.6 (25233.33%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS beat(2) | 1 | Avg EPS beat(2) | -238.98% |
| Min EPS beat(2) | -484.37% | Max EPS beat(2) | 6.42% |
| EPS beat(4) | 1 | Avg EPS beat(4) | -130.84% |
| Min EPS beat(4) | -484.37% | Max EPS beat(4) | 6.42% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | N/A |
| Min Revenue beat(2) | N/A | Max Revenue beat(2) | N/A |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | N/A |
| Min Revenue beat(4) | N/A | Max Revenue beat(4) | N/A |
| PT rev (1m) | 3900% | EPS NQ rev (1m) | 0% |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | N/A |
| Revenue NY rev (1m) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -2.25 | EY | N/A |
| EPS(NY) | -0.42 | Fwd EY | N/A |
| FCF(TTM) | -15.06 | FCFY | N/A |
| OCF(TTM) | -15.06 | OCFY | N/A |
| SpS | N/A | BVpS | -10.44 |
| TBVpS | -10.44 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 2 | Asset Turnover | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.22 | ||
| Quick Ratio | 0.22 | ||
| Altman-Z | -48.16 |
| F-Score | 2 | WACC | N/A |
| ROIC/WACC | N/A | Cap/Depr(3y) | N/A |
| Cap/Depr(5y) | N/A | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | -221.43% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -31.25% |
| EPS Next Y | -78.21% | EPS Next 2Y | 23.02% |
| EPS Next 3Y | 10.02% | EPS Next 5Y | -144.42% |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| EBIT growth 1Y | -205.47% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -231.67% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -231.67% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA